SUBTYPES OF MUSCARINIC RECEPTORS

描述（申请人的摘要）：第一次研讨会的亚型 1983年举行的毒蕈碱受体是第一个探索被忽视的领域， 多年来，除了少数调查人员。作为一项研究的结果， 治疗学的实际问题，毒蕈碱亚型的概念， 受体成为现实，整个研究领域都充满活力， 快速增长。在第一次研讨会以来的短时间内， 根据药理学性质明确定义，并已显示 是不同基因的产物，序列，分布， 已经公开了5种毒蕈碱受体的偶联机制。第九 研讨会将继续先前的先例，增加我们的基本 毒蕈碱受体的知识并公开了新的激动剂和拮抗剂 具有潜在或已证实的治疗价值。研讨会将以 会议的卫星，并与之结合， 神经科学主要目标是提供一个论坛， 正在积极研究毒蕈碱受体功能的人， 研究人员正在积极寻求受体的身份和结构， 从分子克隆技术发展而来的亚型。广阔的领域， 涵盖内容包括：1）分子药理学调节和功能 毒蕈碱受体和与其它系统的相互作用; 2）发育， 药物化学和临床方面的新的，选择性的药物，特别是 泌尿生殖系统和胃肠道系统以及心血管系统 和肺功能，以及3）对毒蕈碱作用的新见解 中枢神经系统中的受体及其与阿尔茨海默氏症的相关性 疾病，精神分裂症，疼痛和青光眼。本次研讨会提供了一个独特的 生物化学家、生理学家、药理学家之间互动的机会 神经科学家是多学科方法的领导者， 年轻的研究人员和博士前研究员，他们将 在海报展示会上展示他们的作品。专题讨论会讨论情况 将在2至3个月内作为《生命科学》的定期刊物出版， 免费发送给成千上万的订阅者

DESCRIPTION (Applicant's Abstract): The First Symposium on Subtypes of Muscarinic Receptors, held in 1983, was the first to probe a field ignored for years by all but a few investigators. As a result of research directed at a practical problem of therapeutics, the concept of subtypes of the muscarinic receptor became a reality and a whole field of research was energized into rapid growth. In the short time since the first symposium 4 subtypes have been clearly defined on the basis of pharmacological properties and have been shown to be the products of distinct genes and the sequences, distribution, and coupling mechanisms of 5 muscarinic receptors have been disclosed. The Ninth Symposium will continue the precedents set previously by increasing our basic knowledge of muscarinic receptors and disclosing new agonists and antagonists of potential or demonstrated therapeutic value. The Symposium will be held as a satellite of, and in conjunction with, the annual meeting of the Society of Neurosciences. The major goals are to provide a forum for interaction between individuals who are actively studying muscarinic receptor function and investigators who are actively pursuing the identity and structure of receptor subtypes with technologies evolved from molecular cloning. The broad areas to be covered include: 1) molecular pharmacology regulation and function of muscarinic receptors and interactions with other systems; 2) development, medicinal chemistry and clinical aspects of new, selective agents, particularly with respect to genito-urinary and gastrointestinal systems, and cardiovascular and pulmonary function, and 3) new insights into the role of muscarinic receptors in the central nervous system and their relevance to Alzheimer's disease, schizophrenia, pain and glaucoma. This symposium provides an unique opportunity for interaction between biochemists, physiologists, pharmacologists and neuroscientists who are the leaders in the multidisciplinary approach being taken in the field and young investigators and predoctoral fellows who will present their work in the poster sessions. The Proceedings of the Symposium will be published within 2 to 3 months as a regular issue of Life Sciences and sent free to its thousands of subscribers.